Adding focused brain radiation to osimertinib for lung cancer in the brain
Original title: Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the treatment is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether focused radiation plus a daily pill controls lung cancer in the brain.
Who this trial is for. This trial is for adults whose lung cancer spread to the brain and causes symptoms. It tests focused brain radiation added to osimertinib, a daily pill for EGFR gene changes.
Where it stands. The trial has not reported results. It is measuring how many people have their brain tumors shrink. It also tracks how long people live and what side effects happen.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about it. The trial team decides who can take part.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not care you can count on. Joining one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.